Is Zepbound or Wegovy better for weight loss?

Zepbound produced 20.2% average weight loss versus 13.7% for Wegovy in the 2025 SURMOUNT-5 head-to-head trial over 72 weeks, a 6.5 percentage point advantage.

Which has worse side effects, Zepbound or Wegovy?

Both share the same gastrointestinal side effect profile. Wegovy showed slightly more vomiting in SURMOUNT-5; Zepbound showed slightly more injection site reactions. Discontinuation for adverse events ran 6.1% for Zepbound versus 8.0% for Wegovy.

Is Zepbound cheaper than Wegovy?

List prices are similar (around $1,086 for Zepbound and $1,349 for Wegovy). Cash programs are close: LillyDirect ships Zepbound for $349 to $499 per month; NovoCare ships Wegovy for $499 after a $199 first-month starter dose.

Can I switch from Wegovy to Zepbound?

Yes. Stop Wegovy on your normal injection day, wait 7 days, then start Zepbound at 2.5 mg and titrate up by 2.5 mg every 4 weeks. Some prescribers start at 5 mg for patients who tolerated Wegovy 2.4 mg.

How does Wegovy HD compare to Zepbound?

Wegovy HD (7.2 mg semaglutide) produced about 21% weight loss in the STEP UP trial, comparable to Zepbound 15 mg in SURMOUNT-1. The two have not been studied head-to-head.

Does insurance cover Zepbound or Wegovy?

Coverage varies. Many commercial plans cover one or both with prior authorization and BMI documentation. Medicare does not cover either for weight loss alone, though some Part D plans now cover Wegovy for cardiovascular risk reduction in patients with obesity and established heart disease.

Which is better for someone with heart disease, Zepbound or Wegovy?

Wegovy. It is FDA approved to reduce major adverse cardiovascular events in adults with obesity and established cardiovascular disease, based on the SELECT trial. Zepbound does not yet have this indication; the SURPASS-CVOT trial is ongoing.

Which is better for obstructive sleep apnea?

Zepbound. It is FDA approved for moderate to severe OSA in adults with obesity. Wegovy is not.

Can I take Zepbound or Wegovy if I have type 2 diabetes?

Both can lower blood sugar, but for diabetes management Mounjaro (tirzepatide) and Ozempic (semaglutide) are the labeled options. Zepbound and Wegovy are labeled for weight management; many prescribers use them off-label or alongside diabetes drugs.

How do Zepbound vs Wegovy vs Ozempic compare?

Zepbound and Wegovy are both labeled for weight loss; Ozempic is labeled for type 2 diabetes. Typical weight loss runs roughly 20% on Zepbound, 14% on Wegovy 2.4 mg, and 6 to 10% on Ozempic 1 to 2 mg.

Zepbound vs Wegovy: Which Weight Loss Drug Wins in 2026?

Summary: In the 2025 SURMOUNT-5 head-to-head trial Zepbound produced 20.2% weight loss versus 13.7% for Wegovy over 72 weeks; cost, side effects, and insurance coverage are close, so the choice usually comes down to weight loss ceiling, prior tolerance, and what your plan will pay for.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: in the 2025 SURMOUNT-5 head-to-head trial, Zepbound produced 20.2% average weight loss versus 13.7% for Wegovy over 72 weeks ^[1]. Both are FDA-approved weekly injections for chronic weight management. Both share the same gastrointestinal side effect profile, the same boxed warning, and similar cash-pay pricing. The deciding factors are usually how much weight you want to lose, what your insurance will cover, and whether you have a specific indication (heart disease, sleep apnea, MASH) that pushes one drug to the front.

Zepbound is tirzepatide, made by Eli Lilly, and acts on two gut hormones (GIP and GLP-1). Wegovy is semaglutide, made by Novo Nordisk, and acts on one (GLP-1 only). That mechanism difference is what drives the weight loss gap.

The mechanism difference

Wegovy is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, slows gastric emptying, increases insulin secretion in response to food, suppresses glucagon, and signals satiety in the brain.

Zepbound is a dual GIP and GLP-1 receptor agonist. It hits the GLP-1 receptor and also activates the receptor for glucose-dependent insulinotropic polypeptide, a second incretin hormone. GIP appears to amplify insulin secretion, increase energy expenditure, and modulate fat storage in ways GLP-1 alone does not.

That second receptor is the reason Zepbound outperforms Wegovy on weight loss in head-to-head data. Whether the GIP arm is doing the work through metabolism, appetite, or both is still debated. The clinical result is not.

Head-to-head weight loss: SURMOUNT-5

SURMOUNT-5 is the only randomized head-to-head trial of tirzepatide against semaglutide in adults with obesity and without type 2 diabetes. It enrolled 751 participants, randomized them to maximum tolerated doses of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg, the full maintenance range), and followed them for 72 weeks ^[1].

Outcome at 72 weeks	Zepbound	Wegovy
Mean weight loss	20.2%	13.7%
Participants losing 15% or more	64.6%	40.1%
Participants losing 20% or more	48.4%	27.3%
Participants losing 25% or more	31.6%	16.1%
Discontinuation for adverse events	6.1%	8.0%

The gap is 6.5 percentage points of body weight in Zepbound's favor. For someone starting at 230 pounds, that is roughly 15 additional pounds lost over 72 weeks. Discontinuations from adverse events were slightly lower with Zepbound, which surprises people who assume the higher-potency drug must be harder on the gut.

Cross-trial context: SURMOUNT-1 and STEP-1

Before SURMOUNT-5 settled the question, the field compared the two through their pivotal weight loss trials.

STEP-1 tested Wegovy at 2.4 mg weekly in 1,961 adults with obesity or overweight and at least one weight-related comorbidity, over 68 weeks. Mean weight loss was 14.9% for semaglutide versus 2.4% for placebo ^[3]. About one-third of treated participants lost 20% or more of body weight.

SURMOUNT-1 tested Zepbound at 5 mg, 10 mg, and 15 mg in 2,539 adults with obesity over 72 weeks. Mean weight loss at the 15 mg dose was 20.9% in the intention-to-treat analysis and as high as 22.5% on-treatment, versus 3.1% for placebo ^[2]. The 5 mg dose alone roughly matched Wegovy's top number.

These trials used different populations, but the pattern they suggested held up when the head-to-head data arrived. Zepbound produces larger average weight loss than Wegovy at maximum tolerated doses.

Side effect profiles

Both drugs share the same dominant side effects: gastrointestinal, dose-dependent, worst during titration, and usually improving once you stabilize at a maintenance dose.

The shared list:

Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain and bloating
Reduced appetite and early satiety
Fatigue, especially in the first weeks
Injection site reactions
Acid reflux and burping

In SURMOUNT-5, GI side effects were common in both arms. Vomiting was reported more often with Wegovy. Injection site reactions occurred slightly more often with Zepbound. Hair loss and hypersensitivity reactions also appear in the Zepbound label at the higher dose tiers ^[4]. Total discontinuation for adverse events ran 6.1% on Zepbound versus 8.0% on Wegovy ^[1], but at the maximum 15 mg Zepbound dose, GI complaints can be more intense than at any Wegovy dose. The dropout numbers favor Zepbound, but individual day-to-day side effect intensity at the top tier is often higher.

Serious side effects shared by both

The boxed warning is identical: a theoretical risk of medullary thyroid carcinoma based on rat studies. Do not use either drug if you or a first-degree relative has medullary thyroid carcinoma or multiple endocrine neoplasia type 2 ^[4]^[5].

Other shared serious risks:

Acute pancreatitis. Stop the drug and call a clinician for severe persistent abdominal pain.
Gallbladder disease, including gallstones and cholecystitis. Rapid weight loss raises baseline risk.
Acute kidney injury, usually from dehydration after vomiting or diarrhea.
Ileus (intestinal blockage), a low-frequency post-marketing signal added to both labels.
Aspiration risk under anesthesia from delayed gastric emptying. Tell your surgical team you are on a GLP-1.
Diabetic retinopathy worsening in people with type 2 diabetes (better documented for semaglutide).
Suicidal thoughts or worsening depression. Both labels flag a precaution; monitor mood changes during titration.

Cost: list price, cash programs, and insurance

The list price for both sits around $1,000 to $1,400 per month, but almost nobody pays sticker. The numbers that matter are insured copay and direct cash programs from each manufacturer.

Pricing channel	Zepbound (tirzepatide)	Wegovy (semaglutide)
List price	~$1,086/month	~$1,349/month
Manufacturer cash pay program	LillyDirect: $349 (2.5 mg vial) to $499 (higher dose vials)	NovoCare Pharmacy: $499/month after a $199 first-month starter
Insured commercial copay	Savings card brings copay to as low as $25/month for covered patients	Savings card brings copay to as low as $0/month for covered patients
Medicare/Medicaid	Not covered for weight loss; covered if Mounjaro is used for type 2 diabetes	Not covered for weight loss; Wegovy now covered by some Part D plans for CV risk reduction in patients with established heart disease and obesity
Compounded versions	FDA declared tirzepatide off the shortage list in late 2024, narrowing legal compounding	Semaglutide still has limited compounding pathways through state-licensed pharmacies

LillyDirect ships Zepbound vials directly to patients without insurance for $349 to $499 per month depending on dose. NovoCare Pharmacy ships Wegovy for $499 per month after a $199 first-month starter dose. The two programs sit close enough that price alone rarely decides the choice. Insurance coverage usually does.

Insurance coverage

Insurance behavior differs by indication, not by drug.

Obesity without diabetes: coverage is uneven. Medicare does not cover weight loss medications under its standard drug benefit. Many commercial plans either exclude weight loss medications or require documented BMI, prior diet program participation, and step therapy. Wegovy and Zepbound have similar coverage profiles; specific formulary tier varies by plan.
Cardiovascular risk reduction: Wegovy gained an FDA indication to reduce major adverse cardiovascular events in adults with obesity and established heart disease. Some Medicare Part D plans now cover it for that indication. Zepbound does not yet have this approval. The SURPASS-CVOT cardiovascular outcomes trial for tirzepatide is expected to read out in late 2026 or 2027.
Obstructive sleep apnea: Zepbound has an FDA indication for moderate to severe OSA in adults with obesity. Wegovy does not. A patient with obesity plus OSA may get Zepbound covered while Wegovy is denied.
MASH (metabolic dysfunction-associated steatohepatitis): Wegovy has accelerated approval. Zepbound does not.

Which indication you qualify under often determines whether you get any coverage at all.

Who Zepbound suits best

Pick Zepbound if your situation aligns with any of the following:

Maximum weight loss is the goal. SURMOUNT-5 put Zepbound 6.5 percentage points ahead ^[1]. If you are starting from a higher BMI or have already plateaued on Wegovy, Zepbound has more headroom.
You have obesity plus obstructive sleep apnea. Zepbound has the FDA indication; Wegovy does not.
You have type 2 diabetes alongside weight to lose. Mounjaro (the diabetes-labeled version of tirzepatide) shows stronger A1C reduction than Ozempic in SURPASS-2, and the same chemistry powers Zepbound.
You experienced inadequate weight loss on Wegovy. Real-world switching from semaglutide to tirzepatide is common and frequently produces additional weight loss.
LillyDirect cash pricing fits your budget. The $349 vial price for the 2.5 mg starting dose is currently the lowest cash entry point for a brand-name weight loss GLP-1.

Who Wegovy suits best

Pick Wegovy if any of these apply:

You have established cardiovascular disease. Wegovy is approved to reduce major adverse cardiovascular events in adults with obesity and heart disease. Zepbound does not yet have this indication.
You have MASH. Wegovy has accelerated FDA approval for MASH; Zepbound does not.
You are an adolescent. Wegovy is approved from age 12 for obesity. Zepbound is not currently approved in adolescents.
Your insurance covers Wegovy but not Zepbound (or vice versa). This is a common real-world decider; tier placement is plan-specific.
You had intolerable side effects on Zepbound. People who could not stay on tirzepatide at the higher doses sometimes do well on Wegovy at 2.4 mg.
You want the cardiovascular outcome data that exists today. SELECT showed semaglutide reduced major adverse cardiac events by 20% in adults with obesity and established heart disease; equivalent tirzepatide data is not yet published.

Recommendation matrix

Your situation	Better starting choice	Why
Maximum weight loss goal	Zepbound	20.2% vs 13.7% in SURMOUNT-5
Obesity plus OSA	Zepbound	FDA OSA indication
Obesity plus established heart disease	Wegovy	FDA cardiovascular indication
Obesity plus MASH	Wegovy	FDA MASH approval
Adolescent (age 12 to 17) with obesity	Wegovy	Only age-approved option
Inadequate response after 6 months on Wegovy	Switch to Zepbound	Common real-world upgrade
Insurance covers only one	The covered one	Cash list is too high to ignore coverage
Cash pay, lowest starter price	Zepbound (LillyDirect 2.5 mg)	$349/month entry

Dosing and titration

Both drugs use a slow, deliberate titration schedule designed around GI tolerability. The starting doses are below therapeutic. The maintenance doses are where the weight loss happens.

Drug	Starting dose (weeks 1 to 4)	Titration	Maintenance dose range
Zepbound	2.5 mg weekly	+2.5 mg every 4 weeks	5, 7.5, 10, 12.5, or 15 mg weekly
Wegovy injection	0.25 mg weekly	Approximate doubling every 4 weeks	1.7 or 2.4 mg weekly
Wegovy HD	After 4 weeks at 2.4 mg	Step up	7.2 mg weekly

Zepbound has six dose strengths (counting the 2.5 mg starting dose). Wegovy has fewer steps. More steps means more chances to find a dose where side effects are manageable, which is part of why discontinuation rates favored Zepbound in SURMOUNT-5.

Wegovy HD vs Zepbound

Wegovy HD is the 7.2 mg high-dose version of semaglutide approved after the standard 2.4 mg dose has been tolerated for at least 4 weeks. In the STEP UP trial, Wegovy HD produced about 21% average weight loss, which closes much of the gap with Zepbound 15 mg at roughly 20.9% in SURMOUNT-1 ^[2].

Wegovy HD has not been studied head-to-head against Zepbound. Cross-trial comparisons in different populations suggest the two are close at the top of the dose curve, but the only direct comparison data (SURMOUNT-5, run before Wegovy HD's approval) used Wegovy at 2.4 mg.

Switching from Wegovy to Zepbound

Switching is common and generally safe under prescriber supervision. There is no required washout period since both drugs target the same general pathway. The standard approach:

Stop Wegovy on your normal injection day.
Wait 7 days.
Start Zepbound at the 2.5 mg starting dose, not at a dose-matched equivalent.
Titrate up by 2.5 mg every 4 weeks as tolerated.

Some prescribers will start at 5 mg in patients who tolerated Wegovy 2.4 mg comfortably. Most restart at 2.5 mg because tirzepatide's GI side effects are dose-dependent and starting low protects the first month. Discuss the plan with your prescriber before you stop Wegovy.

Switching from Wegovy to Zepbound dosage chart

Wegovy dose at switch	Suggested Zepbound starting dose	Notes
0.25 mg	2.5 mg	Standard restart
0.5 mg	2.5 mg	Standard restart
1.0 mg	2.5 mg	Standard restart; some prescribers go to 5 mg
1.7 mg	2.5 to 5 mg	Prescriber discretion
2.4 mg	5 mg	If 2.4 mg was tolerated well for 4+ weeks
Wegovy HD 7.2 mg	5 mg	Resume titration; reach therapeutic Zepbound dose over 8 to 12 weeks

These are general patterns from clinical practice, not FDA-published equivalencies. Your prescriber sets the actual dose.

Switching from Zepbound to Wegovy

The reverse switch is less common and usually driven by insurance changes, cost, or a desire to use the cardiovascular indication. Same principle: stop Zepbound on your normal injection day, wait a week, restart at Wegovy 0.25 mg, and titrate up. Some prescribers start at 0.5 or 1 mg if the patient was tolerating Zepbound at 10 mg or higher. Expect some weight regain during the transition window since Wegovy at 0.25 to 1 mg is below the therapeutic threshold.

Zepbound vs Wegovy vs Ozempic

People shopping the weight loss GLP-1 market often lump Ozempic into the same conversation. The straight answer:

Ozempic is semaglutide (same drug as Wegovy) at lower doses, FDA approved for type 2 diabetes and cardiovascular risk reduction in T2D and chronic kidney disease, not for weight loss.
Wegovy is semaglutide at higher doses, FDA approved for chronic weight management and (in adults with obesity and heart disease) for cardiovascular risk reduction.
Zepbound is tirzepatide, FDA approved for chronic weight management and obstructive sleep apnea.

If your prescription says Ozempic and you want it for weight loss, that is an off-label use. Most commercial insurance plans require Wegovy or Zepbound for weight management, not Ozempic. The data: top-line weight loss runs about 6% to 10% on Ozempic 1 to 2 mg, 13.7% on Wegovy 2.4 mg (SURMOUNT-5 arm) ^[1], and 20.2% on Zepbound 10 or 15 mg (SURMOUNT-5 arm) ^[1].

What this article does not cover

Adjacent questions, like how Mounjaro vs Ozempic compare for diabetes, the deep mechanism comparison of tirzepatide vs semaglutide, retatrutide as the next-generation challenger, or detailed cost optimization through telehealth and compounding pharmacies, have their own dedicated pages on this site. Use the search or sidebar to find them. The framework here, Zepbound's higher weight loss ceiling versus Wegovy's broader indication set, holds across most patient scenarios.

Is Zepbound or Wegovy better for weight loss?: Zepbound produced 20.2% average weight loss versus 13.7% for Wegovy in the 2025 SURMOUNT-5 head-to-head trial over 72 weeks, a 6.5 percentage point advantage.
Which has worse side effects, Zepbound or Wegovy?: Both share the same gastrointestinal side effect profile. Wegovy showed slightly more vomiting in SURMOUNT-5; Zepbound showed slightly more injection site reactions. Discontinuation for adverse events ran 6.1% for Zepbound versus 8.0% for Wegovy.
Is Zepbound cheaper than Wegovy?: List prices are similar (around $1,086 for Zepbound and $1,349 for Wegovy). Cash programs are close: LillyDirect ships Zepbound for $349 to $499 per month; NovoCare ships Wegovy for $499 after a $199 first-month starter dose.
Can I switch from Wegovy to Zepbound?: Yes. Stop Wegovy on your normal injection day, wait 7 days, then start Zepbound at 2.5 mg and titrate up by 2.5 mg every 4 weeks. Some prescribers start at 5 mg for patients who tolerated Wegovy 2.4 mg.
How does Wegovy HD compare to Zepbound?: Wegovy HD (7.2 mg semaglutide) produced about 21% weight loss in the STEP UP trial, comparable to Zepbound 15 mg in SURMOUNT-1. The two have not been studied head-to-head.
Does insurance cover Zepbound or Wegovy?: Coverage varies. Many commercial plans cover one or both with prior authorization and BMI documentation. Medicare does not cover either for weight loss alone, though some Part D plans now cover Wegovy for cardiovascular risk reduction in patients with obesity and established heart disease.
Which is better for someone with heart disease, Zepbound or Wegovy?: Wegovy. It is FDA approved to reduce major adverse cardiovascular events in adults with obesity and established cardiovascular disease, based on the SELECT trial. Zepbound does not yet have this indication; the SURPASS-CVOT trial is ongoing.
Which is better for obstructive sleep apnea?: Zepbound. It is FDA approved for moderate to severe OSA in adults with obesity. Wegovy is not.
Can I take Zepbound or Wegovy if I have type 2 diabetes?: Both can lower blood sugar, but for diabetes management Mounjaro (tirzepatide) and Ozempic (semaglutide) are the labeled options. Zepbound and Wegovy are labeled for weight management; many prescribers use them off-label or alongside diabetes drugs.
How do Zepbound vs Wegovy vs Ozempic compare?: Zepbound and Wegovy are both labeled for weight loss; Ozempic is labeled for type 2 diabetes. Typical weight loss runs roughly 20% on Zepbound, 14% on Wegovy 2.4 mg, and 6 to 10% on Ozempic 1 to 2 mg.